Gubra A/S
CSE:GUBRA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
114
726
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gubra A/S
Common Shares Outstanding
Gubra A/S
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gubra A/S
CSE:GUBRA
|
Common Shares Outstanding
kr16.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chemometec A/S
CSE:CHEMM
|
Common Shares Outstanding
kr17.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Gubra A/S
Glance View
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
See Also
What is Gubra A/S's Common Shares Outstanding?
Common Shares Outstanding
16.3m
DKK
Based on the financial report for Dec 31, 2023, Gubra A/S's Common Shares Outstanding amounts to 16.3m DKK.
What is Gubra A/S's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
0%
Over the last year, the Common Shares Outstanding growth was 0%.
You don't have any saved screeners yet
